Status:
NOT_YET_RECRUITING
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Lead Sponsor:
Antelope Surgical Solutions, Inc
Conditions:
Prostate Cancer
Prostate Cancer (Adenocarcinoma)
Eligibility:
MALE
18-90 years
Phase:
PHASE1
PHASE2
Brief Summary
A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS
Eligibility Criteria
Inclusion
- suspected prostate cancer warranting standard of care multi-core prostate biopsy
Exclusion
- Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment
- Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature
- Patients with a creatinine clearance cutoff (CrCl) of \< 60 mL/min
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06906471
Start Date
December 1 2025
End Date
March 1 2026
Last Update
November 13 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
HCA Florida Kendall Hospital
Miami, Florida, United States, 33175
2
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York, United States, 10029
3
Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan, Taiwan, 333